• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

    7/17/24 4:15:00 PM ET
    $BIOL
    $BTCY
    $DERM
    $ELUT
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BIOL alert in real time by email

    DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies.

    "During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs.

    "Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of stock during the quarter and in July welcomed Adam Rice, CPA as our new Chief Financial Officer."

    SWK anticipates reporting second quarter 2024 results on Thursday, August 15 and will hold a conference call on Friday, August 16.

    Summary of Recent Corporate Highlights:

    • Adam Rice joined SWK as Chief Financial Officer in July.

    • Courtney Baker was promoted from Assistant Controller to Controller in June.

    • During the second quarter of 2024, SWK repurchased 58,567 shares of stock for a total cost of $1.0 million.

    • Year-to-date 2024 through July 15, 2024, SWK has repurchased 197,969 shares of stock for a total cost of $3.4 million.

    New Financings:

    • In May, we funded an additional $2.0 million of term loan to AOTI, Inc. to support the company's continued growth.

    • In June, Journey Medical Corporation ("Journey") drew the $5.0M of additional term loan available under its existing credit agreement with SWK. In July, SWK closed an amendment to allow Journey to draw an incremental $5.0M upon FDA approval of DFD-29, a treatment for rosacea. The FDA's current Prescription Drug User Fee Act (PDUFA) goal date for DFD-29 is November 4, 2024.

    Portfolio Company Updates:

    AOTI, Inc.
    Advanced Oxygen Therapeutics, Inc. (AIM:AOTI) is a medical technology company that develops and markets proprietary wound care therapies.

    • Successfully completed an IPO on the London Stock Exchange's AIM in June 2024, raising gross proceeds of £35.1 million.

    • Generated $43.9M million in revenues for the year ended December 31, 2023.

    Biolase, Inc.
    Biolase, Inc. (OTCQB:BIOL) is a medical device company that develops, manufactures, and markets proprietary dental laser systems.

    • Generated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialists.

    • Third strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptions.

    • Lowered adjusted EBITDA loss by 21% during quarter ended March 31, 2024, versus the same quarter last year.

    Biotricity, Inc.
    Biotricity, Inc. (NASDAQ:BTCY) is a medical technology company focused on delivering remote biometric monitoring solutions to the medical and consumer markets.

    • For the fiscal year ending March 31, 2024, revenues rose by 25% to $12.1 million compared to $9.6 million in the prior year. Gross margin was 69.3% for the fiscal year ending March 31, 2024, as compared to 56.5% in the corresponding prior year, as a result of expansion in recurring technology fee revenue base.

    • In July announced an accelerated timeline to achieve EBITDA positive before the end of calendar 2024

    Elutia
    Elutia Inc. (NASDAQ:ELUT) is a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat.

    • For the quarter ended March 31, 2024, reported year-over-year sales growth of ~28% for proprietary products (specifically CanGaroo and SimpliDerm).

    • In June 2024, announced FDA approval of EluPro (the company's next-generation, drug-eluting version of CanGaroo) and raised gross proceeds of $13.3 million via the sale of common stock and prefunded warrants.

    Eton Pharmaceuticals, Inc.
    Eton (NASDAQ:ETON) is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.

    • Eton reported revenue for the quarter ended March 31, 2024, of $8.0 million, representing 50% growth over March 31, 2023, marking the 13th consecutive quarter of sequential product sales growth.

    • On April 30, 2024, Eton announced the submission to the FDA of New Drug Application ("NDA") for ET-400, Eton's proprietary patented formulation of hydrocortisone oral solution.

    • Acquired the U.S. rights to PKU GOLIKE, which is indicated for Phenylketonuria, from Relief Therapeutics.

    Journey Medical Corporation
    Journey Medical Corporation (NASDAQ:DERM) is a commercial-stage pharmaceutical company focused on commercializing FDA-approved, prescription dermatology products.

    • Total revenues for the first quarter ended March 31, 2024, were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023.

    • Flagship products, Qbrexza and Accutane, grew by greater than 20% year-over-year.

    • Adjusted EBITDA of $11,000 for the first quarter ended March 31, 2024, compared to Adjusted EBITDA of $(5.3 million) for the first quarter of 2023.

    Shield Therapeutics plc (LSE:STX)
    Shield (LSE:STX) is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol).

    • For the quarter ended March 31, 2024, total Accrufer® prescriptions of ~28.8k, up 174% year-over-year.

    • First quarter 2024 Accrufer® revenue of $4.0M at an average net selling price of ~$140/prescription.

    • Established $10.0 million accounts receivable facility with Sallyport Commercial Finance.

    • In May 2024, Korean partner for Accrufer® submitted an NDA with the Korean Ministry of Food and Drug Safety.

    • In July 2024 announced receipt of $5.7 million through the monetization of a China approval milestone payment with AOP Health International Management AG.

    About SWK Holdings Corporation
    SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million. SWK also owns Enteris BioPharma, a clinical development and manufacturing organization providing development services to pharmaceutical partners. Additional information on the life science finance market is available on the Company's website at www.swkhold.com.

    Safe Harbor Statement
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors which, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

    For more information, please contact:
    Ira M. Gostin, MBA, APR
    Investor Relations
    775-391-0213
    [email protected]

    SOURCE: SWK Holdings Corp.



    View the original press release on accesswire.com

    Get the next $BIOL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOL
    $BTCY
    $DERM
    $ELUT

    CompanyDatePrice TargetRatingAnalyst
    Eton Pharmaceuticals Inc.
    $ETON
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    Eton Pharmaceuticals Inc.
    $ETON
    1/10/2025$21.00Buy
    B. Riley Securities
    Eton Pharmaceuticals Inc.
    $ETON
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    Eton Pharmaceuticals Inc.
    $ETON
    9/4/2024$9.00Buy
    H.C. Wainwright
    Journey Medical Corporation
    $DERM
    8/22/2024$9.00Buy
    Rodman & Renshaw
    Journey Medical Corporation
    $DERM
    6/28/2024$11.00Buy
    ROTH MKM
    Eton Pharmaceuticals Inc.
    $ETON
    5/6/2024$8.00Buy
    Craig Hallum
    Biotricity Inc.
    $BTCY
    11/20/2023Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $33.00 from $17.00 previously

      1/23/25 9:02:14 AM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Eton Pharmaceuticals with a new price target

      B. Riley Securities initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $21.00

      1/10/25 7:49:32 AM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Eton Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $17.00 from $15.00 previously

      1/6/25 8:01:16 AM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:30:13 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:28:27 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Opaleye Management Inc. bought $79,814 worth of shares (10,000 units at $7.98) (SEC Form 4)

      4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)

      10/25/24 4:05:24 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Leadership Updates

    Live Leadership Updates

    See more
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

      January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

      1/22/25 8:30:00 AM ET
      $BDRX
      $JNJ
      $SWKH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Diversified Financial Services
      Finance
    • Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

      Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical

      12/3/24 6:50:00 AM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

      - New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today reported strong first-quarter results for 2025 and highlighted key developments driving the adoption of EluPro™. In its first quarter post-launch, EluPro demonstrated strong momentum, establishing its position as a groundbreaking solution for cardiac implantable electronic device (CIED) procedures. Business Highlights: The EluPro™ Revolution is Now Underway: In its first full quarter post-launch, EluPro e

      5/8/25 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

      DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In* (Audio Only)        Click Here Webcast:                          Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can

      5/1/25 4:30:00 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOL
    $BTCY
    $DERM
    $ELUT
    SEC Filings

    See more
    • SEC Form 424B5 filed by Elutia Inc.

      424B5 - ELUTIA INC. (0001708527) (Filer)

      5/8/25 5:12:28 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - ELUTIA INC. (0001708527) (Filer)

      5/8/25 4:25:47 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ELUTIA INC. (0001708527) (Filer)

      5/6/25 4:15:59 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Eton Pharmaceuticals Inc.

      SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

      12/9/24 4:04:43 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      11/29/24 2:00:25 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

      SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

      11/14/24 6:06:28 PM ET
      $BTCY
      Medical/Dental Instruments
      Health Care

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Financials

    Live finance-specific insights

    See more
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

      DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In* (Audio Only)        Click Here Webcast:                          Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can

      5/1/25 4:30:00 PM ET
      $ETON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

      SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13753035 Please log in approximately 10 minutes prior to the scheduled start time. A liv

      5/1/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Maraoui Claude sold $33,065 worth of shares (4,834 units at $6.84), decreasing direct ownership by 0.21% to 2,348,313 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:34:52 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Benesch Joseph sold $16,478 worth of shares (2,409 units at $6.84), decreasing direct ownership by 1% to 203,557 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:34:22 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO Alloush Ramsey sold $19,542 worth of shares (2,857 units at $6.84), decreasing direct ownership by 0.56% to 504,817 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:31:11 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care